Biology original contribution
Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine

https://doi.org/10.1016/0360-3016(95)02134-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (27)

  • B. Fertil et al.

    Mean inactivation dose: A useful concept for intercomparison of human cell survival curves

    Radiat. Res.

    (1984)
  • V. Gandhi et al.

    Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides

    Cancer Res.

    (1990)
  • V. Heinemann et al.

    Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine

    Mol. Pharmacol.

    (1990)
  • Cited by (298)

    • Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer

      2020, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      In this phase 1/2 trial, a 5-week course of intensity modulated radiation therapy (IMRT) (50-57.5 Gy) was given concurrently with weekly fixed-dose-rate (FDR) gemcitabine (1,000 mg/m2 over 100 minutes). FDR gemcitabine infusion likely increases intratumoral concentration of its active metabolite and enhances effects of radiation.16,17 This treatment resulted in a subsequent resection in 12 of 50 patients (24%), with resultant median OS of 32 months in that small cohort.18

    • The Evolving Role of Radiation in Pancreatic Cancer

      2018, Surgical Clinics of North America
    • Overview

      2015, Clinical Radiation Oncology
    View all citing articles on Scopus
    View full text